Vindesine, etoposide (VP-16), and prednisolone (VEP) in relapsed patients with grade II non-Hodgkin's lymphoma.
Vindesine, etoposide (VePesid), and prednisolone (VEP) have been evaluated as a second-line combination regimen in 20 patients with grade II non-Hodgkin's lymphoma (NHL) who relapsed during or after first-line intensive therapy. The overall response rate was 40% (20% complete, of 9 to 13+ months' duration, and 20% partial, of 1.5 to 5 months' duration). The main toxicities were alopecia and myelosuppression (with two nonfatal cases of septicemia); nausea, vomiting, neurotoxicity, and skin and mucosal problems were relatively uncommon. VEP appears to be an active second-line regimen with acceptable toxicity in relapsed high-grade NHL patients.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014751:Vindesine
D014747:Vinblastine; D005047:Etoposide; D011239:Prednisolone; D014751:Vindesine